Cytokinetics, Inc.

Molecular Templates, Inc.

Boehringer Ingelheim International Gmbh

Denise Andersen

Bradley Paul Morgan

Mark D Matteucci

Jian-Xin Duan

Nipun Davar

Matthew Pfeiffer

Norma Tom

Tina Marie Morwick

Yancey David Ward

Roger John Snow

Qi Gao

Asitha Abeywardane

Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.

Process for preparing aficamten

The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.

TH-302 solid forms and methods related thereto

Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases.

Anti-cytokine heterocyclic compounds

Growing community of inventors

Montara, CA, United States of America

Denise Andersen